353
Views
17
CrossRef citations to date
0
Altmetric
Retina

Recombinant Human Nerve Growth Factor Treatment Promotes Photoreceptor Survival in the Retinas of Rats with Retinitis Pigmentosa

, , , ORCID Icon, , , , & show all
Pages 1064-1068 | Received 27 Dec 2015, Accepted 28 Dec 2016, Published online: 01 Mar 2017
 

ABSTRACT

Purpose: Increasing evidence suggests that nerve growth factor (NGF) exerts protective effects against retinal degeneration in animal models of retinitis pigmentosa (RP). This study aims at investigating the effects of intravitreal injection of recombinant human NGF (rhNGF) on retinal photoreceptors apoptosis in an animal model of RP, the Royal College of Surgeons (RCS) rats.

Methods: Thirty-six RCS rats were treated with intravitreal injection of rhNGF or murine NGF (mNGF) or vehicle at 20 postnatal days (pd) and sacrificed at 40 pd. The eyes were enucleated and evaluated by histology, flow cytometric analysis for rhodopsin expression, Western blot for TrkA and activated (phosphorylated) TrkA (pTrkA) levels, and TUNEL assay for apoptosis’ detection.

Results: RCS rats showed a significant retinal degeneration associated with cell apoptosis at 40 pd when compared to wild-type animals. Histology showed that rhNGF intravitreal treatment significantly increased retinal thickness when compared to untreated eyes. Photoreceptors’ number evaluated by flow cytometry was significantly increased in both intravitreal rhNGF- and mNGF-treated groups when compared to untreated eyes. This protective effect was associated with an increase in TrkA and activated pTrkA levels and an inhibition of apoptosis. Intravitreal NGF injection was well tolerated and did not show clinical and histological signs of adverse effects.

Conclusions: Intravitreal rhNGF injection proved safe and effective in favoring retinal cell survival in RCS rats. This is the first report showing that the novel rhNGF already proved safe in a phase I study exerts a biologic effect similar to the well-characterized mNGF-induced retinal protection. These results may trigger further studies to investigate rhNGF administration for the treatment of progressive degenerative retinal disorders such as retinitis pigmentosa.

Declaration of interest

Authors FM and LB are Dompè employees. The other authors report no conflict of interests. The authors alone are responsible for the content and writing of the paper.

Funding

The experiments were partially conducted by Biogem under a contract with Dompé Farmaceutici SPA. The study was supported by Italian Ministry of Health research grant RF-2010-2318561 and by Dompè Farmaceutici SPA. AM was supported by the Italian Ministry of Health and Fondazione Roma (Italy).

Additional information

Funding

The experiments were partially conducted by Biogem under a contract with Dompé Farmaceutici SPA. The study was supported by Italian Ministry of Health research grant RF-2010-2318561 and by Dompè Farmaceutici SPA. AM was supported by the Italian Ministry of Health and Fondazione Roma (Italy).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.